• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corp (NQ: INCY )

    83.38 +1.04 (+1.26%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Incyte Corp

    < Previous 1 2
    ...
    10 11 12 13 14 15 16 17 Next >
    The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    Incyte: Q1 Earnings Insights
    Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M
    Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide. 
    Via Benzinga
    MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland
    The  
    Via Benzinga
    The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
    Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
    Via Benzinga
    3 Nasdaq Stocks to Buy Now for Growth
    These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year. 
    Via InvestorPlace
    Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
    From Incyte
    Via Business Wire
    EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
    Via Benzinga
    Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
    From Incyte
    Via Business Wire
    How To Attend Incyte Q1 2022 Earnings Conference Call
    Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live... 
    Via Benzinga
    Incyte to Report First Quarter Financial Results
    From Incyte
    Via Business Wire
    The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    This Favorable Sign Appears On Incyte's Chart
    If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
    Via Benzinga
    Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder
    Incyte Corporation (NASDAQ: INCY)  
    Via Benzinga
    Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
    At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)  
    Via Benzinga
    Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
    From Incyte
    Via Business Wire
    Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
    From Incyte
    Via Business Wire
    The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
    From Incyte
    Via Business Wire
    FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder
    The FDA has extended the review period for Incyte Corporation's (NASDAQ: INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo... 
    Via Benzinga
    Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
    From Incyte Corporation
    Via Business Wire
    Insiders Buy More Than $80M Of 3 Stocks
    Although US stock futures traded higher this morning on Friday, there were a few notable insider trades. 
    Via Benzinga
    Why Are Company Insiders Buying These 7 S&P 500 Stocks?
    Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying... 
    Via Benzinga
    Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients
    According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in... 
    Via Benzinga
    CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval
    The FDA approved CTI BioPharma Corp's (NASDAQ: CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low... 
    Via Benzinga
    Insiders Buying Incyte And 2 More Stocks
    Although U.S. stock futures traded higher this morning after recording losses on Tuesday, there were a few notable insider trades. When i... 
    Via Benzinga
    7 Insider Stocks to Buy as Execs Snap Them Up
    With equity prices soaring to record levels, many execs have cashed out. Here are the insider stocks where execs are cashing in. 
    Via InvestorPlace
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Insiders Buy Around $112M Of 3 Stocks
    US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades. 
    Via Benzinga
    < Previous 1 2
    ...
    10 11 12 13 14 15 16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.